Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.

Source The Motley Fool

Key Points

  • Kenvue is spending big to drum up demand for its diversified product portfolio.

  • The company's weak results reflect pressure on consumer spending.

  • The stock is a good value and has a high yield.

  • 10 stocks we like better than Kenvue ›

The stock market has historically been a highly effective tool for compounding wealth over time. Another way to use the stock market to achieve your financial goals is to generate income from dividend stocks.

Sometimes, it can make sense to target a stodgy company with a high yield, rather than allocate all your savings into high-octane growth stocks. Maybe you're simply looking to diversify, or maybe you're focused on generating a specific amount of dividends to help supplement income in retirement.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

In that case, it may interest you to know that investing $26,000 into Kenvue (NYSE: KVUE), a high-yield consumer staples stock, could earn you at least $1,000 in dividend income per year. Here's why Kenvue stands out as a solid dividend stock to buy now.

A person smiles while looking in a mirror and applying a skincare product.

Image source: Getty Images.

Kenvue has been struggling since its spinoff

In August 2023, Johnson & Johnson spun off its consumer health and hygiene brands under a new publicly traded company called Kenvue. The idea was to allow J&J to focus on its pharmaceutical and medical technology segments, which generally have higher growth prospects than the consumer health division.

Kenvue has several well-known brands under categories such as:

  • pain relief and fever (Tylenol, Bengay, etc.)
  • allergy and respiratory (Benadryl, Zyrtec, among others)
  • skin and beauty (Neutrogena, Aveeno, Clean & Clear, etc.)
  • oral health brand (Listerine)
  • baby and child-care brands (Johnson's Baby)
  • digestive health (Lactaid)
  • wound care (Band-Aid and Neosporin)

Although established, these brands aren't exactly growing sales at a breakneck pace. It's quite the opposite, in fact. Kenvue's net sales and operating margins have been falling as it struggles to offset inflationary costs and consumer-spending pressures.

To make up for the sluggish growth, Kenvue's Vue Forward initiative aims to achieve $350 million in annualized savings by 2026. The company has also been spending a considerable amount on advertising and investing in innovation.

In its first quarter, Kenvue launched a variety of marketing campaigns for its biggest brands with social media influencers to appeal to Gen Z consumers. The results led to greater penetration in target markets. So far, however, the ad spending, as a whole, hasn't translated to meaningful bottom-line results.

All told, the spinoff hasn't been a success, as measured by Kenvue's results and its underperforming stock price.

Navigating industry challenges

A major challenge for Kenvue has been private-label brands. Consumers looking to reduce spending may turn to them if they perceive the quality of private-label brands are close enough to name-brand Kenvue items. The threat of private label hurts Kenvue's pricing power, which has been a key differentiator in the consumer staples space among companies that have elite portfolios of brands and can justify price hikes and those that don't.

Kenvue has been holding up fairly well despite competition from private-label brands. On its May earnings call, the company said that it hasn't been seeing a shift to private label globally. In fact, private-label penetration in its categories is down slightly.

Kenvue's global exposure gives it a unique advantage, compared to companies that are more domestically focused. In its recent quarter, about half of net sales came from North America.

The global reach allows the company to offset geographic pressures, such as currency-exchange rates or region-specific changes in consumer behavior. It also drives its brand recognition, which is helping the company hold its own against private-label brands.

A high-yield stock at a good value

Kenvue's results have been disappointing, but the stock is a good value and has a high yield. Its forward price-to-earnings ratio (P/E) is just 18.8 at the time of this writing, and its dividend yield is 3.9%. And because Kenvue was spun off from Johnson & Johnson, it inherited its status as a Dividend King -- which is a company that has paid and raised its dividend for at least 50 consecutive years.

Kenvue raised its dividend in July of last year, so another raise could be on the way in the coming weeks.

A worthwhile addition to power a passive-income portfolio

Kenvue's nearly two-year stint as an independent company has included a fair share of bumps. The stock is down from its post-split initial price and earnings are trending in the wrong direction. At first glance, Kenvue looks like a stock to avoid, rather than to invest in, but there's arguably a lot of potential for patient investors.

The company has an excellent line-up of brands across different product categories and at different price points with a global reach. It hasn't done a good job getting the most out of these brands, but it's also been a challenging operating environment for consumer-focused companies.

The consumer staples sector, as a whole, has been selling off as investors gravitate toward higher-growth names amid the broader market rebound. This has pushed companies like Kenvue into the bargain bin.

In sum, Kenvue is reasonably valued and offers a generous yield for investors seeking passive income. The stock is worth a closer look for investors who believe in the company's brands, but some individuals may want to take a wait-and-see approach to the stock until management's efforts yield better results.

Should you invest $1,000 in Kenvue right now?

Before you buy stock in Kenvue, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kenvue wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,010,880!*

Now, it’s worth noting Stock Advisor’s total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of July 14, 2025

Daniel Foelber has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
U.S. Q2 earnings season is coming, JPMorgan and Citi are the first to appearThe US stock Q2 earnings season kicked off, and JPMorgan, Citigroup (C-US), Wells Fargo, Goldman Sachs will be the first to release their results before the market opens on Tuesday.
Author  TradingKey
Yesterday 09: 58
The US stock Q2 earnings season kicked off, and JPMorgan, Citigroup (C-US), Wells Fargo, Goldman Sachs will be the first to release their results before the market opens on Tuesday.
placeholder
Bitcoin extends all-time high rally, but selling activity poses pullback riskDespite the price growth, profit-taking is developing on the side as revealed by a spike in Bitcoin's exchange net inflows.
Author  FXStreet
11 hours ago
Despite the price growth, profit-taking is developing on the side as revealed by a spike in Bitcoin's exchange net inflows.
placeholder
Bitcoin Retreats After Hitting Record High — Drops Below $120KBitcoin (BTC) reversed sharply after reaching a new all-time high of $123,218 the previous night.
Author  TradingKey
11 hours ago
Bitcoin (BTC) reversed sharply after reaching a new all-time high of $123,218 the previous night.
placeholder
Bitcoin Price Retreats After Hitting ATH — Bulls Pause for BreathBTC traded to a new high above $120,000 and recently started a downside correction.
Author  FXStreet
9 hours ago
BTC traded to a new high above $120,000 and recently started a downside correction.
placeholder
Gold price moves closer to three-week peak amid modest USD downtickGold price (XAU/USD) attracts some dip-buying during the Asian session on Tuesday and reverses a major part of the previous day's retracement slide from a nearly three-week high.
Author  FXStreet
4 hours ago
Gold price (XAU/USD) attracts some dip-buying during the Asian session on Tuesday and reverses a major part of the previous day's retracement slide from a nearly three-week high.
goTop
quote